Press Releases

INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)

Posted on February 2, 2023

INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates

Posted on January 31, 2023

INOVIO Provides an Update on Lassa Fever and MERS Programs

Posted on November 17, 2022

INOVIO Reports Financial Results and Highlights for the Third Quarter 2022

Posted on November 8, 2022

INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800

Posted on October 27, 2022

INOVIO to Report Third Quarter 2022 Financial Results on November 8, 2022

Posted on October 25, 2022

INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Posted on October 13, 2022

INOVIO Reports Inducement Grants Under Inducement Plan

Posted on September 1, 2022

INOVIO to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Posted on August 30, 2022

INOVIO Reports Financial Results and Highlights for the Second Quarter 2022

Posted on August 9, 2022

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.